CSIMarket
 
Clearmind Medicine Inc   (CMND)
Other Ticker:  
 
 
Price: $1.2700 $0.07 5.833%
Day's High: $1.27 Week Perf: -10.56 %
Day's Low: $ 1.21 30 Day Perf: -8.63 %
Volume (M): 25 52 Wk High: $ 108.00
Volume (M$): $ 32 52 Wk Avg: $11.00
Open: $1.23 52 Wk Low: $0.92



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees 1
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Clearmind Medicine Inc
We were incorporated in the State of Delaware on May 28, 2014 and are a development stage company. Our company is developing an online service www.caleminder.net that provides a calendar- based greeting and reminder service to assist subscribers in remembering important life events such as birthdays, anniversaries, etc.

Users will register with the system and enter these important dates as well as configure a variety of settings, including when they want to be notified, for example one month prior, two weeks prior, one week prior, etc. Currently the application is web based and not for a mobile download application.



   Company Address: 101 ? 1220 West 6th Avenue Vancouver 0
   Company Phone Number: 536.1016   Stock Exchange / Ticker: NASDAQ CMND
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GOOG        6.35% 
IAC   -1.33%    
META   -0.55%    
PINS   -0.44%    
SNAP   -5.73%    
ZM   -5.34%    
• View Complete Report
   



Clinical Study

Clearmind Medicine Advances Novel Psychedelic Therapy for Alcohol Use Disorder: Key Milestones and Potential Impact

Published Wed, Mar 13 2024 12:14 PM UTC

Clearmind Medicine Inc., a clinical-stage biotech company, has recently achieved significant milestones in its pursuit of using novel psychedelic-derived therapeutics to address major health challenges. This article explores the latest developments in Clearmind Medicine's clinical trial for alcohol use disorder (AUD) patients and its exclusive licensing agreement for cocaine...

Clinical Study

Clearmind Medicine's Innovative Approach to Alcohol Use Disorder Faces Revenue Challenges

Published Fri, Feb 23 2024 12:06 PM UTC

Clearmind Medicine Inc. has recently received approval to commence its Phase I/IIa clinical trial for CMND-100, a unique psychedelic called MEAI, aimed at treating Alcohol Use Disorder (AUD). This groundbreaking development marks the first time that patients with AUD will be offered this proprietary psychedelic treatment. However, the company's financial performance in the t...

Clinical Study

Clearmind Medicine Secures Exclusive Licensing Agreement with Prominent Israeli Research Center to Revolutionize Cocaine Addiction Treatment

Published Thu, Feb 1 2024 1:15 PM UTC

Clearmind Medicine, a pioneering pharmaceutical company focused on innovative solutions for addiction treatment, has recently announced an exclusive, long-term licensing agreement with a top-notch Israeli research center. The agreement revolves around the company's cutting-edge treatment for cocaine addiction, a groundbreaking approach that has already shown promising result...

Contract

Clearmind Medicine Inc. Raises $2.4 Million in Funding to Propel Psychedelic-Derived Therapeutics Development, Outpacing Competitors in a Challenging Market

Published Tue, Jan 16 2024 4:20 PM UTC

Clearmind Medicine Inc., a biotech company dedicated to the discovery and development of innovative psychedelic-derived therapies, recently announced the closure of its registered direct offering, raising approximately $2.4 million in gross proceeds. The company also entered into a simultaneous private placement with institutional investors, further bolstering its financial ...

Contract

Clearmind Medicine Inc. Expands Funding with $2.4 Million Investment, Focusing on Psychedelic-Derived Therapeutics for Untreated Health Conditions

Published Thu, Jan 11 2024 2:28 PM UTC

Clearmind Medicine Inc., a biotech company with a primary focus on the discovery and development of novel psychedelic-derived therapeutics, recently announced the pricing of its $2.4 million registered direct offering and private placement. The company aims to address major under-treated health problems through innovative solutions. This article delves into the latest develo...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com